Development of a miRNA-based diagnostic assay for pancreatic ductal adenocarcinoma

Expert Review of Molecular Diagnostics

Volumn 11, Issue 3, 2011, Pages 249-257

  Szafranska Schwarzbach, Anna E ^a   Adai, Alex T ^a   Lee, Linda S ^b   Conwell, Darwin L ^b   Andruss, Bernard F ^a  

^a ASURAGEN INC   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

CAP; CLIA; laboratory developed test; microRNA; miRNA; pancreatic cancer; pancreatic ductal adenocarcinoma; test validation

Indexed keywords

MICRORNA;

CANCER DIAGNOSIS; CHRONIC PANCREATITIS; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; LABORATORY TEST; PANCREAS ADENOCARCINOMA; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

CALIBRATION; CARCINOMA, PANCREATIC DUCTAL; DIAGNOSIS, DIFFERENTIAL; HUMANS; MICRORNAS; MOLECULAR DIAGNOSTIC TECHNIQUES; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 79953810637     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.11.10     Document Type: Review

References (48)

1. Oto A, Eltorky MA, Dave A et al. Mimicks of pancreatic malignancy in patients with chronic pancreatitis: correlation of computed tomography imaging features with histopathologic findings. Curr. Probl. Diagn. Radiol. 35(5), 199-205 (2006).
2. Zalatnai A. Pathologic diagnosis of pancreatic cancer - facts, pitfalls, challenges. Orv. Hetil. 142(35), 1885-1890 (2001).
3. van Gulik TM, Reeders JW, Bosma A et al. Incidence and clinical findings of benign, inflammatory disease in patients resected for presumed pancreatic head cancer. Gastrointest. Endosc. 46(5), 417-423 (1997).
4. Gudjonsson B, Livstone EM, Spiro HM. Cancer of the pancreas: diagnostic accuracy and survival statistics. Cancer 42(5), 2494-2506 (1978).
5. Szafranska AE, Davison TS, John J et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26(30), 4442-4452 (2007). Establishes the first comprehensive tissue miRNA expression profiles of normal pancreas, chronic pancreatitis and pancreatic ductal adenocarcinoma (PDAC), leading to the identification of a subset of 26 miRNAs deregulated in PDAC and selection of a simple two-miRNA classifier that allows differentiation of PDAC from chronic pancreatitis.
6. Bloomston M, Frankel WL, Petrocca F et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297(17), 1901-1908 (2007).
7. Szafranska AE, Doleshal M, Edmunds HS et al. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin. Chem. 54(10), 1716-1724 (2008). Builds on [5] and evaluates the utility of miRNA expression profiles in fine-needle aspirate (FNA) samples to reliably identify the disease status of pancreatic tissue.
8. Szafranska AE, Davison TS, Shingara J et al. Accurate molecular characterization of formalin-fixed, paraffin-embedded tissues by microRNA expression profiling. J. Mol. Diagn. 10(5), 415-423 (2008).
9. Doleshal M, Magotra AA, Choudhury B, Cannon BD, Labourier E, Szafranska AE. Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues. J. Mol. Diagn. 10(3), 203-211 (2008).
10. Giovannetti E, Funel N, Peters GJ et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 70(11), 4528-4538 (2010).
11. Sempere LF, Preis M, Yezefski T et al. Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered microRNA expression in solid tumors. Clin. Cancer Res. 16(16), 4246-4255 (2010).
12. Liss B, Roeper J. Correlating function and gene expression of individual basal ganglia neurons. Trends Neurosci. 27(8), 475-481 (2004).
13. Peters IR, Helps CR, Hall EJ, Day MJ. Real-time RT-PCR: considerations for efficient and sensitive assay design. J. Immunol. Methods 286(1-2), 203-217 (2004).
14. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26, 404-413 (1934).
15. Krishna NB, Mehra M, Reddy AV, Agarwal B. EUS/EUS-FNA for suspected pancreatic cancer: influence of chronic pancreatitis and clinical presentation with or without obstructive jaundice on performance characteristics. Gastrointest. Endosc. 70(1), 70-79 (2009).
16. Horwhat JD, Paulson EK, McGrath K et al. A randomized comparison of EUS-guided FNA versus CT or US-guided FNA for the evaluation of pancreatic mass lesions. Gastrointest. Endosc. 63(7), 966-975 (2006).
17. Gress F, Michael H, Gelrud D et al. EUS-guided fine-needle aspiration of the pancreas: evaluation of pancreatitis as a complication. Gastrointest. Endosc. 56(6), 864-867 (2002).
18. Yeo CJ, Cameron JL, Sohn TA et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann. Surg. 226(3), 248-57; discussion 257-260 (1997).
19. Fernandez-del Castillo C, Rattner DW, Warshaw AL. Standards for pancreatic resection in the 1990s. Arch. Surg. 130(3), 295-299; discussion 299-300 (1995).
20. Smith SL, Hampson F, Duxbury M, Rae DM, Sinclair MT. Computed tomography after radical pancreaticoduodenectomy (Whipple's procedure). Clin. Radiol. 63(8), 921-928 (2008).
21. Welsch T, Degrate L, Zschabitz S, Hofer S, Werner J, Schmidt J. The need for extended intensive care after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Langenbecks Arch. Surg. 396(3), 353-362 (2011).
22. Tran TC, van Lanschot JJ, Bruno MJ, van Eijck CH. Functional changes after pancreatoduodenectomy: diagnosis and treatment. Pancreatology 9(6), 729-737 (2009).
23. Fritscher-Ravens A, Brand L, Knofel WT et al. Comparison of endoscopic ultrasound-guided fine needle aspiration for focal pancreatic lesions in patients with normal parenchyma and chronic pancreatitis. Am. J. Gastroenterol. 97(11), 2768-2775 (2002).
24. Agarwal B, Abu-Hamda E, Molke KL, Correa AM, Ho L. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer. Am. J. Gastroenterol. 99(5), 844-850 (2004).
25. Graham RA, Bankoff M, Hediger R, Shaker HZ, Reinhold RB. Fine-needle aspiration biopsy of pancreatic ductal adenocarcinoma: loss of diagnostic accuracy with small tumors. J. Surg. Oncol. 55(2), 92-94 (1994).
26. Takahashi K, Yamao K, Okubo K et al. Differential diagnosis of pancreatic cancer and focal pancreatitis by using EUS-guided FNA. Gastrointest. Endosc. 61(1), 76-79 (2005).
27. Taylor B. Carcinoma of the head of the pancreas versus chronic pancreatitis: diagnostic dilemma with significant consequences. World J. Surg. 27(11), 1249-1257 (2003).
28. Brugge WR. Cystic lesions of the pancreas. Curr. Treat. Options Gastroenterol. 5(5), 325-330 (2002).
29. Visser BC, Yeh BM, Qayyum A, Way LW, McCulloch CE, Coakley FV. Characterization of cystic pancreatic masses: relative accuracy of CT and MRI. AJR Am. J. Roentgenol. 189(3), 648-656 (2007).
30. Gerke H, Jaffe TA, Mitchell RM et al. Endoscopic ultrasound and computer tomography are inaccurate methods of classifying cystic pancreatic lesions. Dig. Liver Dis. 38(1), 39-44 (2006).
31. Khalid A, Zahid M, Finkelstein SD et al. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest. Endosc. 69(6), 1095-1102 (2009).
32. Sawhney MS, Devarajan S, O'Farrel P et al. Comparison of carcinoembryonic antigen and molecular analysis in pancreatic cyst fluid. Gastrointest. Endosc. 69(6) 1106-1110 (2009).
33. Grote T, Logsdon CD. Progress on molecular markers of pancreatic cancer. Curr. Opin. Gastroenterol. 23(5), 508-514 (2007).
34. Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, Whang EE. A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells. Cancer Res. 64(11), 3987-3993 (2004).
35. Habbe N, Koorstra JB, Mendell JT et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol. Ther. 8(4), 340-346 (2009).
36. Wang J, Chen J, Chang P et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev. Res. (Phila.) 2(9), 807-813 (2009). Proof-of-concept study, which demonstrated the feasibility of developing a sensitive and specific blood-based miRNA assay for pancreatic cancer using miR-21, miR-210, miR-155 and miR-196a (sensitivity: 64%, specificity: 89%; AUC: ∼0.8).
37. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18(10), 997-1006 (2008). Demonstrated the association of miRNAs with tumor-derived exosomes circulating in human blood, potentially extending the utility of exosomal miRNA profiling to patient screening.
38. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110(1), 13-21 (2008).
39. Pancreatic Cancer www.cancer.org/acs/groups/cid/documents/webcontent/ 003131-pdf.pdf Contains updated, detailed information on pancreatic cancer, key statistics, risk factors, signs and symptoms, diagnostic tools and procedures and treatment modalities.
40. College of American Pathologists www.cap.org
41. Centers for Medicare & Medicaid Services (CMS) www.cms.gov/clia
42. Clinical Laboratory Improvement Amendments (CLIA) www.fda.gov/ MedicalDevices/DeviceRegulationandGuidance/IVDRegulatoryAssistance/ucm124105. htm General knowledge US FDA online resource for Clinical Laboratory Improvement Amendments-related information.
43. Announcement of FDA Intent to Regulate LDTs www.fda.gov/MedicalDevices/ NewsEvents/WorkshopsConferences/ucm212830.htm#session
44. Clinical Laboratory Standards Institute www.clsi.org
45. Association for Molecular Pathology www.amp.org
46. Standards for the Reporting of Diagnostic Accuracy Studies statement www.stard-statement.org
47. US FDA www.fda.gov
48. Diseases of the Pancreas. Opportunities and Challenges in Digestive Diseases Research: Recommendations of the National Commission on Digestive Diseases 2009 www2.niddk.nih.gov/Research/ScientificAreas/DigestiveDiseases/ Gastrointestinal/PANC.htm